ABBV
NYSE · Biotechnology
Abbvie Inc
$201.55
-1.16 (-0.57%)
ABBV News20 articles
Oruka Therapeutics Soars on Psoriasis Drug Data, Announces $500M Offering
Oruka Therapeutics shares surged after interim data showed its psoriasis drug ORKA-001 achieved 63.5% complete skin clearance. The company also announced a $500M public offering.
J&J Q1 Earnings Surpass Expectations, Lifts 2026 Forecast
Johnson & Johnson exceeded Wall Street's first-quarter forecasts, driven by strong performance from Darzalex and Tremfya. The company raised its full-year 2026 sales guidance.
SCHD ETF Sees Strong Q1 Inflows After Dividend Hike and Portfolio Overhaul
The Schwab U.S. Dividend Equity ETF (SCHD) reported a 3.3% dividend increase and $4 billion in first-quarter inflows following a significant portfolio reshuffle that boosted healthcare and tech exposure while reducing energy holdings.
Eli Lilly Inks $2.75B AI Drug Deal, Posts Positive Trial Data
Eli Lilly has entered a licensing deal with Insilico Medicine potentially worth $2.75 billion and reported strong late-stage clinical results for its immunology and obesity drugs.
Merck's $6.7B Terns Buyout Anchors Stock Near Offer Price
Merck has agreed to acquire Terns Pharmaceuticals in a $6.7 billion all-cash deal. Terns shares traded at $52.86, close to Merck's $53-per-share offer, as investors weigh the deal's completion.
AbbVie's Early Obesity Drug Trial Shows Promising Weight Loss Results
AbbVie reported its amylin-based obesity candidate ABBV-295 led to significant weight reduction in an early study, with no serious safety issues observed. The data marks a strategic step for the company as it seeks growth beyond immunology.
Pfizer's Eczema Candidate Tilrekimig Advances, Eyes Dupixent Rivalry
Pfizer announced its experimental eczema drug tilrekimig achieved its main goal in a mid-stage study, showing significant symptom improvement. The company plans to initiate a pivotal Phase 3 trial later this year.
J&J Shares Dip on Lupus Drug Fast Track, Investors Eye Legal Risks
Johnson & Johnson shares declined 0.7% to $245.07 Wednesday after the FDA granted Fast Track designation to its lupus drug candidate nipocalimab, lagging behind a strong market advance.
AbbVie Gains on $8 Billion Bond Sale, Outperforms Slumping Market
AbbVie shares climbed 3.29% to $232.08 on Friday, defying a broader market decline. The pharmaceutical giant is set to raise approximately $7.95 billion through a seven-part bond sale settling March 4.
AbbVie's $1.73 Dividend Payout Arrives Amid Regulatory and Market Headwinds
AbbVie shares gained 1.8% to close at $231.50 Friday ahead of a $1.73 per share dividend payment on Tuesday. The company faces regulatory challenges and competitive pressures despite solid quarterly revenue.
AbbVie Gains Ahead of Holiday; Investors Eye Pipeline and Pricing
AbbVie shares advanced 1.8% to $231.50 in Friday's session, outpacing peers. Trading volume was elevated as investors assess the company's strategic pivot and regulatory challenges.
Healthcare ETF Rises on Dexcom, Moderna Earnings; Markets Eye Holiday
Healthcare stocks advanced Friday, with the XLV ETF rising 1.1% as Dexcom and Moderna posted strong quarterly results. U.S. markets are closed Monday for the Presidents Day holiday.
Merck Shares Surge to 52-Week High on Deutsche Bank Upgrade
Merck shares climbed to a 52-week high following an upgrade from Deutsche Bank, which raised its price target to $150. The company is set to present new bladder and kidney cancer data later this month.
Pfizer Shares Dip in Premarket Amid SEC Settlement, Partnership News
Pfizer stock edged lower in premarket trading following a $29 million SEC settlement agreement and a new biotech incubator partnership. Investors await key inflation data.
AbbVie Gains as Analyst Target Hike Meets Macroeconomic Caution
AbbVie shares advanced Tuesday after BNP Paribas Exane raised its price target, while broader markets were mixed as traders awaited delayed U.S. jobs and inflation data.
Eli Lilly shares retreat as $2.4B Orna acquisition and China partnership draw scrutiny
Eli Lilly's stock declined 0.9% as investors assessed the company's strategic moves into cell therapy and Chinese drug development. The market is weighing increased pipeline spending against intensifying competition in obesity treatments.
Eli Lilly Shares Dip Following $2.4 Billion Orna Therapeutics Acquisition Announcement
Eli Lilly shares declined 1.3% in after-hours trading after announcing a $2.4 billion acquisition of Orna Therapeutics. Investors are monitoring the deal's impact on Lilly's pipeline and upcoming regulatory decisions.
Merck Shares Slide 4% on Patent Concerns and 2026 Outlook
Merck & Co. stock fell nearly 4% Monday, underperforming the broader market as investors reacted to projected patent losses and a cautious 2026 sales forecast.
AbbVie Gains on Moody's Credit Upgrade, Focus Shifts to Immunology Portfolio
AbbVie shares rose 2% to $223.43 after Moody's upgraded its credit rating to A2 with a stable outlook. Investors now watch demand and pricing for Skyrizi and Rinvoq amid Humira competition.
AbbVie Shares Gain 2% to Close Near $223 Amid Earnings Volatility, Credit Upgrade
AbbVie stock rose 2% Friday, ending a turbulent week marked by earnings scrutiny and a Moody's credit rating upgrade. Investors remain focused on Skyrizi and Rinvoq growth amid competitive pressures.